Home Biosimilar Antibodies Others Others Anti-Complement C2 (ARGX-117)
For research use only. Not for use in humans.

Anti-Complement C2 (ARGX-117)

Synonyms: Complement component C2， C2

Anti-Complement C2 (ARGX-117) is a monoclonal antibody that inhibits complement factor C2. It inhibits complement in a disease model for multifocal motor neuropathy. MW: 146.12 kD.

Anti-Complement C2 (ARGX-117)

Quality Control

Batch: A270102 Purity: 99% Protein concentration: 9.83mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Anti-Complement C2 (ARGX-117) is a monoclonal antibody that inhibits complement factor C2. It inhibits complement in a disease model for multifocal motor neuropathy. MW: 146.12 kD.
References

Product Details

Molecular Weight 146.12
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05405361 ACTIVE_NOT_RECRUITING Multifocal Motor Neuropathy (MMN) argenx 2023-01-18 PHASE2
NCT05907096 ACTIVE_NOT_RECRUITING Delayed Graft Function argenx 2024-02-17 PHASE2
NCT05225675 COMPLETED Multifocal Motor Neuropathy argenx 2022-03-31 PHASE2
NCT04532125 COMPLETED Healthy Volunteers argenx 2020-08-03 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-03-11)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.